Triterpenic Acid Amides as a Promising Agent for Treatment of Metabolic Syndrome

Triterpenic Acid Amides as a Promising Agent for Treatment of Metabolic Syndrome Full article

Journal

Scientia Pharmaceutica
ISSN: 0036-8709 , E-ISSN: 2218-0532

Output data

Year: 2021, Volume: 89, Number: 1, Article number : 4, Pages count : 14 DOI: 10.3390/scipharm89010004

Tags

Glucose tolerance; Hypoglycemic activity; Natural product; Total cholesterol; Triterpenic amides; Type 2 diabetes mellitus

Authors

Fomenko Vladislav ¹ , Blokhin Mikhail ¹ , Kuranov Sergey ¹ , Khvostov Mikhail ¹ , Baev Dmitriy ¹ , Borisova Marina S. ¹ , Luzina Olga ¹ , Tolstikova Tatyana G. ¹ , Salakhutdinov Nariman F. ¹

Affiliations

1	N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry

A series of triterpenic acid amides were synthesized incorporating a 2-ethoxy-3-phenylpropanoic acid pharmacophore fragment. The synthesized compounds were tested for their ability to improve glycemic control and to counter lipid abnormalities in C57BL/6 mice placed on a high-fat/high-cholesterol diet. Of all tested compounds, the dihydrobetulonic derivative (16b) had the most pronounced effect in decreasing blood glucose levels, total cholesterol (TC), and high-density lipoproteins (HDL). All the synthesized compounds displayed a relatively safe profile in the animal studies carried out in this work.

Fomenko V. , Blokhin M. , Kuranov S. , Khvostov M. , Baev D. , Borisova M.S. , Luzina O. , Tolstikova T.G. , Salakhutdinov N.F.
Triterpenic Acid Amides as a Promising Agent for Treatment of Metabolic Syndrome

Scientia Pharmaceutica. 2021. V.89. N1. 4 :1-14. DOI: 10.3390/scipharm89010004 WOS Scopus РИНЦ

Full text from publisher

Submitted:	Dec 1, 2020
Accepted:	Dec 23, 2020
Published online:	Dec 29, 2020

Web of science	WOS:000651876800001
Scopus	2-s2.0-85098970681
Elibrary	45026299
OpenAlex	W3117112876